Kos settles Advicor name dispute with Andrx
Executive Summary
Andrx will end use of the Altocor name and pay $6 mil. to settle trademark dispute over Kos' cholesterol product Advicor. Settlement ends litigation in Philadelphia federal appeals court. Kos' original complaint in New Jersey federal court sought to enjoin Andrx from using Altocor name for its extended-release lovastatin; that motion was denied. Andrx will now market its product as Altoprev, a name approved by FDA in August 2003 (1"The Pink Sheet" May 10, 2004, In Brief)...